PURPOSE: Metaiodobenzylguanidine (MIBG) scans are a radionucleotide imaging modality that undergo Curie scoring to semiquantitatively assess neuroblastoma burden, which can be used as a marker of therapy response. We hypothesized that a convolutional neural network (CNN) could be developed that uses diagnostic MIBG scans to predict response to induction chemotherapy. METHODS: We analyzed MIBG scans housed in the International Neuroblastoma Risk Group Data Commons from patients enrolled in the Children's Oncology Group high-risk neuroblastoma study ANBL12P1. The primary outcome was response to upfront chemotherapy, defined as a Curie score ≤ 2 after four cycles of induction chemotherapy. We derived and validated a CNN using two-dimensional whole-body MIBG scans from diagnosis and evaluated model performance using area under the receiver operating characteristic curve (AUC). We also developed a clinical classification model to predict response on the basis of age, stage, and MYCN amplification. RESULTS: Among 103 patients with high-risk neuroblastoma included in the final cohort, 67 (65%) were responders. Performance in predicting response to upfront chemotherapy was equivalent using the CNN and the clinical model. Class-activation heatmaps verified that the CNN used areas of disease within the MIBG scans to make predictions. Furthermore, integrating predictions using a geometric mean approach improved detection of responders to upfront chemotherapy (geometric mean AUC 0.73 v CNN AUC 0.63, P < .05; v clinical model AUC 0.65, P < .05). CONCLUSION: We demonstrate feasibility in using machine learning of diagnostic MIBG scans to predict response to induction chemotherapy for patients with high-risk neuroblastoma. We highlight improvements when clinical risk factors are also integrated, laying the foundation for using a multimodal approach to guiding treatment decisions for patients with high-risk neuroblastoma.
PURPOSE: Metaiodobenzylguanidine (MIBG) scans are a radionucleotide imaging modality that undergo Curie scoring to semiquantitatively assess neuroblastoma burden, which can be used as a marker of therapy response. We hypothesized that a convolutional neural network (CNN) could be developed that uses diagnostic MIBG scans to predict response to induction chemotherapy. METHODS: We analyzed MIBG scans housed in the International Neuroblastoma Risk Group Data Commons from patients enrolled in the Children's Oncology Group high-risk neuroblastoma study ANBL12P1. The primary outcome was response to upfront chemotherapy, defined as a Curie score ≤ 2 after four cycles of induction chemotherapy. We derived and validated a CNN using two-dimensional whole-body MIBG scans from diagnosis and evaluated model performance using area under the receiver operating characteristic curve (AUC). We also developed a clinical classification model to predict response on the basis of age, stage, and MYCN amplification. RESULTS: Among 103 patients with high-risk neuroblastoma included in the final cohort, 67 (65%) were responders. Performance in predicting response to upfront chemotherapy was equivalent using the CNN and the clinical model. Class-activation heatmaps verified that the CNN used areas of disease within the MIBG scans to make predictions. Furthermore, integrating predictions using a geometric mean approach improved detection of responders to upfront chemotherapy (geometric mean AUC 0.73 v CNN AUC 0.63, P < .05; v clinical model AUC 0.65, P < .05). CONCLUSION: We demonstrate feasibility in using machine learning of diagnostic MIBG scans to predict response to induction chemotherapy for patients with high-risk neuroblastoma. We highlight improvements when clinical risk factors are also integrated, laying the foundation for using a multimodal approach to guiding treatment decisions for patients with high-risk neuroblastoma.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: J Clin Epidemiol Date: 2008-04 Impact factor: 6.437
Authors: Navin Pinto; Arlene Naranjo; Emily Hibbitts; Susan G Kreissman; M Meaghan Granger; Meredith S Irwin; Rochelle Bagatell; Wendy B London; Emily G Greengard; Julie R Park; Steven G DuBois Journal: Eur J Cancer Date: 2019-04-01 Impact factor: 9.162
Authors: Kevin Campbell; Julie M Gastier-Foster; Meegan Mann; Arlene H Naranjo; Collin Van Ryn; Rochelle Bagatell; Katherine K Matthay; Wendy B London; Meredith S Irwin; Hiroyuki Shimada; M Meaghan Granger; Michael D Hogarty; Julie R Park; Steven G DuBois Journal: Cancer Date: 2017-07-11 Impact factor: 6.860
Authors: Gregory A Yanik; Marguerite T Parisi; Arlene Naranjo; Helen Nadel; Michael J Gelfand; Julie R Park; Ruth L Ladenstein; Ulrike Poetschger; Ariane Boubaker; Dominique Valteau-Couanet; Bieke Lambert; Maria-Rita Castellani; Zvi Bar-Sever; Aurore Oudoux; Anna Kaminska; Susan G Kreissman; Barry L Shulkin; Katherine K Matthay Journal: J Nucl Med Date: 2017-09-08 Impact factor: 10.057
Authors: Ruth Ladenstein; Bieke Lambert; Ulrike Pötschger; Maria-Rita Castellani; Valerie Lewington; Zvi Bar-Sever; Aurore Oudoux; Anna Śliwińska; Katerina Taborska; Lorenzo Biassoni; Gregory A Yanik; Arlene Naranjo; Marguerite T Parisi; Barry L Shulkin; Helen Nadel; Michael J Gelfand; Katherine K Matthay; Julie R Park; Susan G Kreissman; Dominique Valteau-Couanet; Ariane Boubaker Journal: Eur J Nucl Med Mol Imaging Date: 2017-09-23 Impact factor: 9.236
Authors: M Meaghan Granger; Arlene Naranjo; Rochelle Bagatell; Steven G DuBois; Jeannine S McCune; Sheena C Tenney; Brian D Weiss; Yael P Mosse; Shahab Asgharzadeh; Stephen A Grupp; Michael D Hogarty; Julie M Gastier-Foster; Denise Mills; Barry L Shulkin; Marguerite T Parisi; Wendy B London; John Han-Chang; Joseph Panoff; Daniel von Allmen; Jason A Jarzembowski; Julie R Park; Gregory A Yanik Journal: Transplant Cell Ther Date: 2021-03-06
Authors: James P B O'Connor; Eric O Aboagye; Judith E Adams; Hugo J W L Aerts; Sally F Barrington; Ambros J Beer; Ronald Boellaard; Sarah E Bohndiek; Michael Brady; Gina Brown; David L Buckley; Thomas L Chenevert; Laurence P Clarke; Sandra Collette; Gary J Cook; Nandita M deSouza; John C Dickson; Caroline Dive; Jeffrey L Evelhoch; Corinne Faivre-Finn; Ferdia A Gallagher; Fiona J Gilbert; Robert J Gillies; Vicky Goh; John R Griffiths; Ashley M Groves; Steve Halligan; Adrian L Harris; David J Hawkes; Otto S Hoekstra; Erich P Huang; Brian F Hutton; Edward F Jackson; Gordon C Jayson; Andrew Jones; Dow-Mu Koh; Denis Lacombe; Philippe Lambin; Nathalie Lassau; Martin O Leach; Ting-Yim Lee; Edward L Leen; Jason S Lewis; Yan Liu; Mark F Lythgoe; Prakash Manoharan; Ross J Maxwell; Kenneth A Miles; Bruno Morgan; Steve Morris; Tony Ng; Anwar R Padhani; Geoff J M Parker; Mike Partridge; Arvind P Pathak; Andrew C Peet; Shonit Punwani; Andrew R Reynolds; Simon P Robinson; Lalitha K Shankar; Ricky A Sharma; Dmitry Soloviev; Sigrid Stroobants; Daniel C Sullivan; Stuart A Taylor; Paul S Tofts; Gillian M Tozer; Marcel van Herk; Simon Walker-Samuel; James Wason; Kaye J Williams; Paul Workman; Thomas E Yankeelov; Kevin M Brindle; Lisa M McShane; Alan Jackson; John C Waterton Journal: Nat Rev Clin Oncol Date: 2016-10-11 Impact factor: 66.675